An audit of protocol deviations submitted to an institutional ethics committee of a Tertiary Care Hospital

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Jalgaonkar, Sharmila V ^a   Bhide, Shruti S ^a   Tripathi, Raakhi K ^a   Shetty, Yashashri C ^a   Marathe, Padmaja A ^a   Katkar, Janhavi ^a   Thatte, Urmila M ^a  

^a KEM HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL STUDY; COUNSELING; HUMAN; INFORMED CONSENT; INSTITUTIONAL ETHICS; PRACTICE GUIDELINE; RISK ASSESSMENT; TERTIARY CARE CENTER; MANAGEMENT; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PROFESSIONAL STANDARD; RETROSPECTIVE STUDY; TERTIARY HEALTH CARE;

ETHICS COMMITTEES, RESEARCH; HUMANS; MANAGEMENT AUDIT; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN; RETROSPECTIVE STUDIES; TERTIARY HEALTHCARE;

EID: 84954066920     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0146334     Document Type: Article

References (17)

1. USFDA. Compliance Program Guidance Manual. Inspectional Chapter. Section D3. Available: http://www.fda.gov/downloads/ICECI/EnforcementActions/BioresearchMonitoring/ucm133773.pdf. Accessed 10 November 2013.
2. International Conference on Harmonisation. Guideline for good clinical practice E6(R1), Current step 4 version.. 1996. Available: http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline.pdf. Accessed 10 November 2013.
3. CDSCO. Good Clinical Practice Guidelines. 2001. Available: http://rgcb.res.in/wp-content/uploads/2014/07/Good-Clinical-Practice-Guideline.pdf. Accessed 13 November 2013.
4. NIH IRB Professional Administrators Committee. Regulatory Process Workgroup Version. 2005. Available: https://www.genome.gov/Pages/Research/Intramural/IRB/Deviation-Violation-examples8-07.pdf. Accessed 13 November 2013.
5. Sweetman EA, Doig GS. Failure to report protocol violations in clinical trials; a threat to internal validity? Trials. 2011;28(12):214.
6. Shetty YC, Marathe PA, Kamat SK, Thatte UM. Continuing oversight through site monitoring: Experiences of an institutional ethics committee in an Indian tertiary-care hospital. Indian J Med Ethics. 2012;9(1):22-26. PMID: 22319848.
7. Kuyare SS, Marathe PA, Shetty YC, Kamat SK, Katkar JV, Thatte UM. Projects not initiated by investigators: A retrospective analysis of the queries raised by the institutional ethics committees of a teaching hospital. J Postgrad Med. 2014;60(1):46-50. doi: 10.4103/0022-3859.128808 PMID: 24625939.
8. Murthy V, Awatagiri KR, Tike PK, Ghosh-Laskar S, Gupta T, Budrukkar A, et al. Prospective analysis of reasons for non-enrollment in a phase III randomized controlled trial. J Cancer Res Ther. 2012;8 Suppl 1:S94-9. doi: 10.4103/0973-1482.92221 PMID: 22322738.
9. Lamberti MJ, Mathias A, Myles JE, Howe D, Getz K. Evaluating the Impact of Patient Recruitment and Retention Practices. Drug Information Journal. 2012;46(5):573-80. doi: 10.1177/0092861512453040
10. Fleming TR. Addressing Missing Data in Clinical Trials. Ann Intern Med. 2011;154(2):113-117. doi: 10.1059/0003-4819-154-2-201101180-00010 PMID: 21242367.
11. Harel O, Pellowski J, Kalichman S. Are we missing the importance of missing values in HIV prevention Randomized clinical trials? Review and Recommendations. AIDS Behav. 2012;16(6):1382-1393. doi: 10.1007/s10461-011-0125-6 PMID: 22223301.
12. Lele C, Sharma S, Bhatt D. Safety data management for clinical trials. Journal for Clinical Studies. 2013;5(5):51-54.
13. Yao B, Zhu L, Jiang Q, Xia HA. Safety Monitoring in Clinical Trials. Pharmaceutics 2013;5:94-106. doi: 10.3390/pharmaceutics5010094 PMCID: PMC4208666.
14. Ministry of Health and Family Welfare (Department of Health), India. G. S. R. 53 (E) notification. 2013. Available: http://cdsco.nic.in/writereaddata/GSR%2053 (E).pdf. Accessed 12 November 2013.
15. Gogtay NJ, Doshi BM, Kannan S, Thatte UM. A study of warning letters issued to clinical investigators and institutional review boards by the United States Food and Drug Administration. Indian Journal of Medical Ethics. 2011;8(4):211-4. PMID: 22106658.
16. Shetty YC, Saiyed AA. Analysis of warning letters issued by the US Food and Drug Administration to clinical investigators, institutional review boards and sponsors: a retrospective study. Journal of Medical Ethics. 2014;41(5):398-403. doi: 10.1136/medethics-2013-101829 PMID: 24965716.
17. Mandava A, Millum J. Manipulation in the Enrollment of Research Participants. Hastings Cent Rep. 2013;43(2):38-47. doi: 10.1002/hast.144 PMID: 23390007.